ES2632928T3 - Procedimiento de cultivo de linfocitos B simples - Google Patents

Procedimiento de cultivo de linfocitos B simples Download PDF

Info

Publication number
ES2632928T3
ES2632928T3 ES11722402.2T ES11722402T ES2632928T3 ES 2632928 T3 ES2632928 T3 ES 2632928T3 ES 11722402 T ES11722402 T ES 11722402T ES 2632928 T3 ES2632928 T3 ES 2632928T3
Authority
ES
Spain
Prior art keywords
antibody
igg
mouse
fitc
lymphocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11722402.2T
Other languages
English (en)
Inventor
Josef Endl
Natalie Schuhmacher
Sonja Offner
Josef Platzer
Basile Siewe
Irmgard Thorey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2632928T3 publication Critical patent/ES2632928T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/231—Interleukin-10 (IL-10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1157—Monocytes, macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1185—Thymus cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/70—Non-animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • G01N2015/016—White blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Procedimiento de selección de un linfocito B que comprende las etapas siguientes: a) cocultivar cada uno de los linfocitos B de una población de linfocitos B, que se ha depositado como célula simple, con células EL-4 B5 murinas como células alimentadoras, b) seleccionar un clon de linfocitos B que haga proliferar y segregue anticuerpo en la etapa a), en la que el cocultivo es en presencia de una mezcla alimentadora sintética que comprende IL-1β, TNFα, IL-10, y uno o más seleccionados de IL-21, SAC, BAFF, IL-2, IL-4 e IL-6.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
Se pueden marcar linfocitos B de ratón con el anticuerpo anti-CD27 235 o 236 (AB 235, AB 236), el anticuerpo anti-CD38 192 (AB 192), el anticuerpo anti-CD138 233 (AB 233) y el anticuerpo anti-CD268 246 (AB 246).
Tabla 5: Marcado por inmunofluorescencia para la determinación de linfocitos B de ratón (A-J), hámster (K) y conejo (L-N) maduros.
marcado
Marcado por inmunofluorescencia para separación linfocitos B de Porcentaje de todas las células viables %
A
IgG+CD19+ -AB 227 FITC, AB 218 PE 0,5 ± 0,2 n = 14
B
IgG+CD38+ -AB 227 FITC, AB 192 PE 0,8 ± 0,5 n = 9
C
IgG+CD138+ -AB 227 FITC, AB 233 PE 0,06 ± 0,07 n = 6
D
IgG+CD138+ -AB 227 FITC, AB 233 PE 0,6 ± 0,5 n = 6
E
IgG+CD27+ -AB 227 FITC, AB 235 PE 0,1 ± 0,1 n = 8
F
CD27+CD138+ -AB 236 A647, AB 233 PE 1,5 ± 0,5 n = 2
G
CD27+IgG+CD3 -AB 235 PE, AB 227 FITC, AB 241 A647 0,10 ± 0,04 n = 3
H
CD3 -CD27+ -AB 189 FITC, AB 235 PE 1,33 n = 1
I
IgG+CD268+ -AB 227 FITC, AB 246 A647 0,8 n = 1
J
CD38+ CD3+ -AB 192 A647, AB 189 PE 12 ± 7 n = 2
K
IgG+IgM -AB 213 A647, AB 224 FITC 0,6 ± 0,1 n = 15
L
IgG+ -AB 184 FITC 0,6 ± 0,2, n = 5
M
IgG+IgM -AB 184 FITC, AB 254 Biotina, SA 263 PE 0,4 ± 0,2, n = 2
N
IgG+CD138+ -AB 259, AB 256 PE 0,3 ± 0,1, n = 5
AB 184 -anticuerpo IgG anti-conejo de cabra AbD Serotec STAR121F AB 189 -anticuerpo CD3 anti-ratón de hámster Becton Dickinson 553062 AB 192 -anticuerpo CD38 anti-ratón de rata Becton Dickinson 553764 AB213 -anticuerpo IgG anti-hámster de ratón Becton Dickinson 554010 AB218 -anticuerpo CD19 anti-ratón de rata Abcam ab22480 AB224 -anticuerpo IgG anti-hámster de ratón Becton Dickinson 554033 AB227 -anticuerpo IgG anti-ratón de cabra Sigma F 8264 AB233 -anticuerpo CD138 anti-ratón de rata Becton Dickinson 553714 AB235 -anticuerpo CD27 anti-ratón de hámster Becton Dickinson 558754 AB236 -anticuerpo CD27 anti-ratón de hámster Becton Dickinson 558753 AB241 -anticuerpo CD3 anti-ratón de hámster Becton Dickinson 553060 AB246 -anticuerpo BAFF-R anti-ratón de rata eBioscience 51-5943 AB254 -anticuerpo IgM anti-conejo de ratón Becton Dickinson personalizado AB256 -anticuerpo IgG anti-rata de cabra Southern Biotech 3030-09 AB259 -anticuerpo CD138 anti-conejo de rata Roche Glycart AG SA 263 -Estreptavidina Invitrogen S866 A647: Alexa Fluor® 647 FITC: Isotiocianato de fluoresceína
En un modo de realización los procedimientos comprenden la etapa de reducir la población de linfocitos B de 10 macrófagos y enriquecer los linfocitos B de la población de linfocitos B que segregan anticuerpos que se unen de forma específica a un antígeno diana.
Depósito de células simples:
15 El procedimiento del que se informa en el presente documento comprende la etapa de depositar los linfocitos B de una población de linfocitos B como células simples. En un modo de realización de todos los procedimientos de los que se informa en el presente documento el depósito como células simples es por separación de células activadas
10
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20

Claims (1)

  1. imagen1
ES11722402.2T 2010-05-28 2011-05-26 Procedimiento de cultivo de linfocitos B simples Active ES2632928T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10005602 2010-05-28
EP10005602.7A EP2400298B1 (en) 2010-05-28 2010-05-28 Single B-cell cultivation method and specific antibody production
PCT/EP2011/058616 WO2011147903A1 (en) 2010-05-28 2011-05-26 Single b-cell cultivation method

Publications (1)

Publication Number Publication Date
ES2632928T3 true ES2632928T3 (es) 2017-09-18

Family

ID=42396427

Family Applications (3)

Application Number Title Priority Date Filing Date
ES10005602T Active ES2434256T3 (es) 2010-05-28 2010-05-28 Método de cultivo de células B individuales y producción de anticuerpos específicos
ES17169362T Active ES2858450T3 (es) 2010-05-28 2011-05-26 Procedimiento de cultivo de linfocitos B individuales
ES11722402.2T Active ES2632928T3 (es) 2010-05-28 2011-05-26 Procedimiento de cultivo de linfocitos B simples

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES10005602T Active ES2434256T3 (es) 2010-05-28 2010-05-28 Método de cultivo de células B individuales y producción de anticuerpos específicos
ES17169362T Active ES2858450T3 (es) 2010-05-28 2011-05-26 Procedimiento de cultivo de linfocitos B individuales

Country Status (15)

Country Link
US (4) US20130084637A1 (es)
EP (4) EP2400298B1 (es)
JP (3) JP5779239B2 (es)
KR (1) KR101495976B1 (es)
CN (2) CN105039252B (es)
BR (1) BR112012025695B1 (es)
CA (2) CA2798286C (es)
DK (1) DK2400298T3 (es)
ES (3) ES2434256T3 (es)
HK (2) HK1181112A1 (es)
MX (2) MX2012013437A (es)
PL (2) PL2400298T3 (es)
RU (1) RU2709531C2 (es)
SI (1) SI2400298T1 (es)
WO (1) WO2011147903A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201403365TA (en) * 2011-12-21 2014-07-30 Hoffmann La Roche Rapid method for cloning and expression of cognate antibody variable region gene segments
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
EP2727942A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Bispecific antibodies against human EGFR, HER2, and HER3
US20150259430A1 (en) 2012-11-05 2015-09-17 Mab Discovery Gmbh Method for the production of multispecific antibodies
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
EP2727943A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Trispecific antibodies against human EGFR, HER2 and HER3
PT2971039T (pt) 2013-03-14 2020-05-06 Immusoft Corp Métodos para diferenciação e transdução in vitro de células b de memória com vetores virais pseudotipados vsv-g
KR20150140679A (ko) 2013-03-15 2015-12-16 앨더 바이오파마슈티컬즈, 인코포레이티드 항원-특이적 b 세포를 확인하고 단리시키고, 원하는 항원에 대한 항체를 생성하기 위한 프로토콜
CN104232577B (zh) * 2013-06-20 2017-12-01 中国人民解放军军事医学科学院基础医学研究所 一种获得自身反应性b细胞的方法
WO2015099534A1 (en) * 2013-12-24 2015-07-02 Aimm Therapeutics B.V. Ex vivo antibody production
WO2016207304A2 (en) 2015-06-26 2016-12-29 Mab Discovery Gmbh Monoclonal anti-il-1racp antibodies
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
EP3436571B1 (en) 2016-03-30 2023-06-14 F. Hoffmann-La Roche AG B-cell cultivation method
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
CN106222137A (zh) * 2016-08-24 2016-12-14 南昌大学 一种体外活化人记忆性b细胞成浆细胞的培养方法
EP3554515A4 (en) 2016-12-15 2020-08-26 Duke University B10 REGULATORY CELL DEPLETION ANTIBODIES AND METHODS AND THEIR USE IN COMBINATION WITH IMMUNITY CHECKPOINT INHIBITORS
JP6916884B2 (ja) * 2017-01-02 2021-08-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ細胞培養法
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
EP3625332B1 (en) 2017-05-19 2022-02-02 F. Hoffmann-La Roche AG Method for the production of thymocyte supernatant
US20210135223A1 (en) * 2017-11-08 2021-05-06 Sharp Kabushiki Kaisha Negative electrode for batteries, battery, and method for producing battery
WO2019105864A1 (en) 2017-11-30 2019-06-06 F. Hoffmann-La Roche Ag B-cell cultivation method
CN108588019B (zh) * 2018-05-03 2019-04-02 首都医科大学附属北京朝阳医院 一种体外诱导初始b细胞分化为调节性b细胞的方法及其培养条件
CN109234232A (zh) * 2018-09-30 2019-01-18 杭州华安单抗生物技术有限公司 兔外周血b细胞的培养体系及培养方法、抗体的制备方法和应用
WO2020141145A1 (en) * 2018-12-30 2020-07-09 F. Hoffmann-La Roche Ag Anti-rabbit cd19 antibodies and methods of use
WO2021211997A1 (en) * 2020-04-16 2021-10-21 The General Hospital Corporation B cell immunomodulatory therapy for acute respiratory distress syndrome
CN111518765B (zh) * 2020-05-12 2021-01-26 优睿赛思(武汉)生物科技有限公司 一种b淋巴细胞体外培养体系及应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58116678A (ja) * 1981-12-28 1983-07-11 Ajinomoto Co Inc 浮遊性動物細胞の培養法およびその装置
JPS58216125A (ja) * 1982-06-09 1983-12-15 Asahi Chem Ind Co Ltd ヒト抗体の産生方法
AU7767191A (en) * 1990-04-17 1991-11-11 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Feeder cells for monoclonal antibody production
US5387940A (en) * 1993-07-07 1995-02-07 Rca Thomson Licensing Corporation Method and apparatus for providing scaleable compressed video signal
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6541225B1 (en) * 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
WO2002014481A1 (fr) * 2000-08-16 2002-02-21 Takara Bio Inc. Procede de culture extensive de lymphocytes t cytotoxiques specifiques de l'antigene
US20060051348A1 (en) 2004-09-09 2006-03-09 Jorn Gorlach Method of producing a plurality of isolated antibodies to a plurality of cognate antigens
US20070031550A1 (en) 2005-08-15 2007-02-08 Samson Allan D Method for continuously processing meat substrates
WO2007031550A2 (en) * 2005-09-15 2007-03-22 Crucell Holland B.V. Method for preparing immunoglobulin libraries
CA2625619A1 (en) * 2005-10-14 2007-04-26 Medimmune, Inc. Cell display of antibody libraries
NZ600075A (en) * 2005-12-09 2013-12-20 Amc Amsterdam Means and methods for influencing the stability of antibody producing cells
NZ569816A (en) * 2005-12-16 2011-10-28 Ribovax Biotechnologies Sa Methods for obtaining immortalized antibody secreting cells
US20070269868A1 (en) * 2006-05-19 2007-11-22 Carvalho Jensen Anne E Culture method for obtaining a clonal population of antigen-specific B cells
US8642307B2 (en) 2006-05-25 2014-02-04 Nalge Nunc International Corporation Cell culture surface chemistries
NZ581596A (en) 2007-05-21 2012-02-24 Alderbio Holdings Llc Antibodies to il-6 and use thereof
US8404235B2 (en) * 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8394583B2 (en) * 2008-07-24 2013-03-12 The Board Of Regents Of The University Of Texas System VH4 codon signature for multiple sclerosis
CA2738566C (en) * 2008-10-01 2024-04-30 Micromet Ag Bispecific single chain antibodies with specificity for high molecular weight target antigens
MX2011003855A (es) * 2008-10-22 2011-12-16 Inst Research In Biomedicine Metodos para producir anticuerpos a partir de celulas plasmaticas.
EP2233502A1 (en) * 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
SG175305A1 (en) * 2009-04-23 2011-11-28 Theraclone Sciences Inc Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
WO2011046623A2 (en) * 2009-10-16 2011-04-21 Duke University Hiv-1 antibodies

Also Published As

Publication number Publication date
US20160251621A1 (en) 2016-09-01
EP2400298A1 (en) 2011-12-28
RU2709531C2 (ru) 2019-12-18
US20180298335A1 (en) 2018-10-18
US20130084637A1 (en) 2013-04-04
EP2400298B1 (en) 2013-08-14
CA3008822C (en) 2020-08-25
BR112012025695A2 (pt) 2016-07-05
CA3008822A1 (en) 2011-12-01
CA2798286A1 (en) 2011-12-01
HK1212731A1 (zh) 2016-06-17
PL3239708T3 (pl) 2021-06-14
EP3239708A1 (en) 2017-11-01
JP5779239B2 (ja) 2015-09-16
ES2858450T3 (es) 2021-09-30
CA2798286C (en) 2019-05-28
WO2011147903A1 (en) 2011-12-01
EP3239708B1 (en) 2021-01-06
ES2434256T3 (es) 2013-12-16
KR20130030758A (ko) 2013-03-27
CN105039252A (zh) 2015-11-11
DK2400298T3 (da) 2013-09-02
RU2015155197A (ru) 2019-01-16
EP3825690A1 (en) 2021-05-26
US20210062149A1 (en) 2021-03-04
RU2015155197A3 (es) 2019-07-17
CN102918395B (zh) 2015-09-09
HK1181112A1 (en) 2013-11-01
MX345884B (es) 2017-02-22
EP2577304B1 (en) 2017-05-10
EP2577304A1 (en) 2013-04-10
MX2012013437A (es) 2013-01-22
PL2400298T3 (pl) 2014-01-31
KR101495976B1 (ko) 2015-02-25
BR112012025695B1 (pt) 2022-06-21
RU2012153785A (ru) 2014-07-10
SI2400298T1 (sl) 2013-11-29
CN102918395A (zh) 2013-02-06
JP2017169579A (ja) 2017-09-28
JP6204415B2 (ja) 2017-09-27
JP2013526286A (ja) 2013-06-24
CN105039252B (zh) 2019-05-28
JP6353953B2 (ja) 2018-07-04
JP2015211690A (ja) 2015-11-26

Similar Documents

Publication Publication Date Title
ES2632928T3 (es) Procedimiento de cultivo de linfocitos B simples
JP4974892B2 (ja) 臍帯血由来のｔ調節性細胞の単離および増殖の方法
Roberto et al. The early expansion of anergic NKG2Apos/CD56dim/CD16neg natural killer represents a therapeutic target in haploidentical hematopoietic stem cell transplantation
MX2019011897A (es) Celulas efectoras inmunitarias especificas de antigenos.
WO2019147805A3 (en) Regulatory t cells targeted with chimeric antigen receptors
Arandi et al. Evaluation of CD4+ CD25+ FOXP3+ regulatory T cells function in patients with common variable immunodeficiency
EP4289944A3 (en) Method for preparing genetically-modified t cells which express chimeric antigen receptor
JP2016509840A5 (es)
RU2013113933A (ru) Антитело к cd38 и леналтдомид или бортезомиб для лечения множественной миеломы и nhl
RU2018110364A (ru) Усовершенствованное продуцирование иммуноглобулинов
Di Ianni et al. Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation
KR20200051046A (ko) 포유동물 세포 배양
BR112012026766A2 (pt) métodos in vitro para gerar uma proteína heterodimérica, para a seleção de um anticorpo biespecífico e para inibir o crescimento, vetor de expressão, célula hospedeira, proteína heterodimérica, composição farmacêutica.
US20190262400A1 (en) Artificial antigen presenting cells for expanding immune cells for immunotherapy
HRP20171753T1 (hr) Pripravci i postupci za proizvodnju glikoproteina
NZ715246A (en) Improved process for production of monoclonal antibodies
WO2014146074A3 (en) Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens
Zongyi et al. Interleukin-35 mitigates the function of murine transplanted islet cells via regulation of Treg/Th17 ratio
JP2023501381A (ja) Ｓｔｅｍ細胞からのキメラ抗原受容体修飾ｔ細胞の作製とその治療的使用
JP2017516486A5 (es)
WO2009131605A3 (en) Fusion partner cell line for preparation of hybrid cells expressing human antibodies
WO2012178150A3 (en) Methods for developing antigen-specific antibody-producing cell lines and monoclonal antibodies
SG10201808061WA (en) Method for the clarification of high density crude cell culture harvest
Schetelig et al. Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial
RU2017101195A (ru) Способы культивирования клеток и среды, предусматривающие n-ацетилцистеин